Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

Phase 2 Terminated 56 enrolled Lecia V. Sequist Beth Israel Deaconess Medical Center · collab Brigham and Women's Hospital · collab Bristol-Myers Squibb · collab Dana-Farber Cancer Institute · collab Unity Health Toronto · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to find out how well cetuximab works in treating NSCLC in patients who have been previously treated with a class of drug called tyrosine kinase inhibitor (TKI). Cetuximab is a protein that is designed to block a substance in cancer cells called "epidermal growth factor receptor" or EGFR. EGFR helps cancer cells grow.

Timeline

Start: 2006-09
Primary completion: 2009-09
Completion: 2009-09

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Publications

Results Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Thorac Oncol. 2010 Nov;5(11):1855-8. doi: 10.1097/JTO.0b013e3181f0bee0.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetuximab	Monoclonal antibody	250 mg/m2	Intravenous